6. Dose aims to improve the lives of those affected by type 2 diabetes by offering
completely personalised health services and non-invasive blood glucose level
measurements.
9. DOSE
Key Players:
Diabetes patients
NHS
Government
Private Hospitals
Meet their
Needs:
Potential diabetics
IBM
UC San Diego
Media
Show
Consideration:
Novartis UK Ltd.
GlaxoSmithKline plc.
Astra Zeneca UK Ltd.
Least
Important:
General public
Average Joe: Hates injections, lazy, demotivated, but loves his phone
Differentiation
Licensing
B2B
Suggested selling price of £93.75 per unit
Cash flow projections ready, prove why profit in 1st year, highlight app as future revenue stream, if we can’t get the license – back-up plan (similar products). Bring up that UCSD has the license, so easier to get than if it was a company. Look into grants